NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Heron Therapeutics, Inc. (HRTX) Stock Analysis

Heron Therapeutics, Inc. (HRTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

HRTX

$0.34

+$0.01 (+3.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HRTX with… →

HRTX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.34
Previous Close
$0.33
Day's Range
0.33–0.36
52-Week Range
0.30–1.58
Volume
1.87M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.61
Valuation
Market Cap
$65.29M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.43
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.19
Financials (FY)
Revenue (FY)
$154.90M+7.36%
Net Income (FY)
−$20.20M
Profit marginThe share of revenue left as profit after all costs and taxes.
−22.52%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
189.85M
1-Year Return
−74.24%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
3.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HRTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−73.85%
2025−15.03%
2024−10.00%
2023−32.00%
2022−72.62%
2021−56.87%
2020−9.91%
2019−9.41%
2018+43.31%
2017+38.17%
2016 (partial year)−30.10%

As of September 4, 2026.

HRTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$154.90M−$20.20M−13.0%
2024$144.29M−$13.58M−9.4%
2023$127.04M−$110.56M−87.0%
2022$107.67M−$182.02M−169.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$154.90M$113.56M−$2.54M−$20.20M−13.0%
2024$144.29M$105.64M−$11.53M−$13.58M−9.4%
2023$127.04M$61.94M−$110.62M−$110.56M−87.0%
2022$107.67M$52.80M−$174.66M−$182.02M−169.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HRTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricHRTXBiotechnology medianvs median
P/S ratio0.4315.260.0x the median
Profit margin−22.52%0.00%22.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Heron Therapeutics, Inc. (HRTX) at $65.29M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 128.

The most recent close on file for HRTX is $0.34, dated September 4, 2026. That is +$0.01 (+3.03%) against the previous close. The 52-week range on file runs from $0.30 to $1.58. The latest close sits 13.33% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $154.90M. That is +7.36% against the prior fiscal year, when revenue was $144.29M. The same year closed with a net loss of $20.20M. The reported profit margin is −22.52%. That is 22.5 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.19.

Across the 4 fiscal years on file, revenue moves from $107.67M in 2022 to $154.90M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 0.43. On price-to-sales that is 0 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −74.24%. Measured over 10 years, that is −32.65% a year compounded. Beta against the wider market is reported at 1.62. Annualized volatility over the trailing 10 years is 76.99%.

Growth & Income

No dividend is on file for HRTX.

2026 is still running; the price is −73.85% year to date. The strongest complete calendar year on file is 2018 at +43.31%; the weakest is 2022 at −72.62%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Heron Therapeutics, Inc. (HRTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Heron Therapeutics, Inc. HRTX $65.29M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Heron Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

Visit website →